Richardson DL, Moore KN, Vergote I, Gilbert L, et al. Phase 1b study of mirvetuximab soravtansine, a folate receptor alpha (FRalpha)-targeting antibody-drug conjugate, in combination with carboplatin and bevacizumab in patients with platinum-sensitive ovarian cancer. Gynecol Oncol 2024;185:186-193.
PMID: 38447347